Factor | Median TTP (months) | 95% CI | SE* | p = |
---|---|---|---|---|
Age > 65 years | 6 vs. 7 | 0.00-12.79 | 3.36 | n.s. |
 |  | 5.64-8.36 | 0.7 |  |
Age < 35 years | 3 vs. 7 | 0.23-5.77 | 1.41 | 0.026 |
 |  | 5.67-8.33 | 0.68 |  |
Stage 4 at diagnosis | 6 vs. 7 | 5.52-8.48 | 0.76 | n.s. |
 |  | 0.39-11.61 | 2.86 |  |
Grading (1,2 versus 3) | 6 vs. 7 | 2.98-9.03 | 1.54 | n.s. |
 |  | 5.6-8.41 | 0.72 |  |
Histologic type (ductal versus lobular) | 6 vs. 9 | 4.86-7.14 | 0.58 | n.s. |
 |  | 0.71-17.29 | 4.23 |  |
Positive hormone receptor status | 6 vs. 7 | 4.64-7.36 | 0.7 | n.s. |
 |  | 5.14-8.86 | 0.95 |  |
Time to recurrence < 12 months | 6 vs. 7 | 3.41-8.59 | 1.32 | n.s. |
 |  | 5.61-8.39 | 0.71 |  |
Visceral metastases | 7 vs. 6 | 5.76-8.25 | 0.64 | n.s. |
 |  | 0.00-12.53 | 3.33 |  |
Number of metastatic sites (1 versus 2) | 14 vs. 6 | 9.56-18.44 | 2.26 | 0.013 |
 |  | 5.02-6.98 | 0.5 |  |
Number of metastatic sites (2 versus > 2) | 8 vs. 6 | 5.58-10.42 | 1.23 | 0.003 |
 |  | 5.09-6.91 | 0.47 |  |
Trastuzumab from first-line palliative treatment | 7 vs. 6 | 5.62-8.38 | 0.71 | n.s. |
 |  | 4.65-7.35 | 0.69 |  |
Response to first-line trastuzumab-based therapy | 7 vs. 6 | 5.25-8.75 | 0.89 | n.s. |
 |  | 3.77-8.23 | 1.14 |  |
New metastatic sites at progression upon first-line trastuzumab-based therapy | 7 vs. 6 | 4.81-9.19 | 1.12 | n.s. |
 |  | 5.12-6.88 | 0.45 |  |